Sanofi-Aventis' Accomplia shows long-term weight loss
A Phase III study of Sanofi-Aventis' Accomplia (rimonabant) in obese and overweight individuals has concluded that it reduces cardiovascular risk factors such as waist circumference and body weight.
Preliminary results from the multinational, multicenter, randomized, double-blind and placebo-controlled RIO-Europe trial were released last year and the final results support the initial findings (Marketletter September 6, 2004).
Among patients completing the study, waist circumference was reduced 7.5cm in those treated with rimonabant 20mg/day for the full two-year period versus 3.4cm for subjects in the placebo group and 59.7% of individuals in the 20 mg/day group lost more than 5.0% of their initial body weight vs 23.4% of those taking placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze